Sekizaki T, Kameda H, Nomoto H, et al. - In this multicenter observational case-control study, researchers sought to examine the impacts of DPP-4 inhibitor (DPP-4i) administration on Graves' disease (GD) activity. Participants in the study were patients with GD and type 2 diabetes, who were administered an oral hypoglycemic agent including DPP-4i. In total, 80 patients were recruited and divided into an exacerbation group or a non-exacerbation group. The frequency of DPP-4i administration in the exacerbation group (88%) was significantly higher than in the non-exacerbation group (31%). There was a significant association between DPP-4i administration and GD exacerbation in multivariate logistic regression analysis. According to the findings of the current study, DPP-4i administration is linked to GD exacerbation.